ENTEROME’S MISSION: TO IMPROVE PATIENT HEALTH BY TRANSLATING THE MOLECULAR UNDERSTANDING OF THE ROLE OF THE HUMAN GUT MICROBIOME TO DELIVER INNOVATIVE MEDICINES.

Enterome is a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.

Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, which play a central role in the regulation of key aspects of human physiology and the immune system.

CROHN DISEASE & IBD

Inflammatory bowel disease is a disorder characterized by chronic and relapsing intestinal inflammation, mainly defined as either Crohn’s disease or ulcerative colitis, and is currently treated in a progressive manner with pharmaceuticals and ultimately, surgery.

Crohn’s disease is a chronic, progressive and incurable disease characterized by inflammation of the gastrointestinal tract.

Our approach is designed to remain gut-restricted and to block bacteria expressing the bacterial virulence factor, FimH, a key inducer of the inflammatory cascade in the intestine, thereby decreasing intestinal inflammation in patients with Crohn’s disease.

MORE ABOUT

IMMUNO-ONCOLOGY

Immuno-oncology is an emerging field of cancer therapy that aims to activate the immune system to enhance and/or create anti-cancer immune responses, as well as to overcome the immuno-suppressive mechanisms that cancer cells have developed against the immune system.

Our cancer immunotherapy solution aims to deliver onco-mimics, or microbiome-derived antigens, which are bacterial-derived short peptides that have high amino acid sequence homology with known human tumor antigens, such as tumor-associated antigens, or TAAs, tumor specific antigens or neoantigens. The goal is to induce efficient presentation of these onco-mimics to T cells that, in turn, leads to a sustained immune response against cancer cells expressing the homologous antigens at the tumor site.

 

MORE ABOUT

AUTOIMMUNE DISEASES

Autoimmune diseases develop when the immune system, natural body defense against disease, consider the healthy cells as foreign. Therefore this dysregulation of the immune system attack healthy cells. Autoimmune diseases can affect many different types of body tissue.

They affect at least 5% of the population.

In the absence of curative therapy, treatment for autoimmune diseases focuses only on relieving symptoms.

COLLABORATIONS

In 2016, Enterome has entered with BMS into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.

The collaboration will combine Bristol-Myers Squibb’s expertise in the discovery and development of novel immunotherapies with Enterome’s proprietary metagenomic technology platform and leadership in the rapidly advancing science of the gut microbiome to support the discovery of novel immunotherapy agents and biomarkers. There is a growing body of scientific evidence to suggest that the gut microbiome plays an important role in modulating mechanisms of response and resistance to cancer immunotherapies. Changes in a host’s immune system driven by the gut microbiome can be exploited to identify specific targets and bioactive compounds with the potential to augment anti-cancer immune responses.

In January 2016, Enterome has announced a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The agreement, facilitated by Johnson & Johnson Innovation, is focused on the discovery of novel targets and bioactive molecules from the gut microbiome for the potential development of therapeutic solutions to Crohn’s disease.

The collaboration aims to advance the characterization and therapeutic validation of these bacterial products, increase knowledge of the regulation of immunity and gut homeostasis, and potentially lead to the development of new therapeutic solutions for Crohn’s disease.

The Janssen Human Microbiome Institute will also join the collaboration to help accelerate the translation of microbiome science into therapeutic solutions in the area of Crohn’s disease.

In January 2016, Enterome has announced a strategic drug discovery collaboration with Takeda Pharmaceutical, to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).

In October 2018, Enterome has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.

LEADERSHIP

MANAGEMENT TEAM

PIERRE BELICHARD

pb

Pierre Belichard has served as our Chief Executive Officer since 2011 and as a member of our board of directors since 2011. Previously, Dr. Belichard served as Vice President of Mergers and Acquisitions and Business Development at Sanofi Ophthalmology from 2009 to 2011. Dr. Belichard was the Founder of Fovea Pharmaceuticals SA. and served as the Chief Operating Officer from 2005 to 2009. From 2002 to 2004, Dr. Belichard served as Vice President of Business Development at UroGene, S.A., a company acquired by Pierre Fabre in 2004. From 2000 to 2002, he served as head of European commercial operations at Ethypharm S.A. Dr. Belichard holds a Pharm.D. from Grenoble Faculty of Medicine and Pharmacy, Ph.D. from University Pierre and Marie Curie and an M.B.A. from INSEAD. Our board of directors believes that Dr. Belichard’s leadership of our company since its inception and experience with biopharmaceutical companies prior to founding our company provides him with the qualifications and skills to serve as a director.

CHIEF EXECUTIVE OFFICER

SIMON BAERISWYL

Simon Baeriswyl has served as our Chief Operating Officer since 2016. From 2012 to 2016, Dr. Baeriswyl worked at Sanofi S.A., serving as External Innovation Director from 2012 to 2014 and Science & External Innovation Chief of Staff from 2014 to 2016. From 2008 to 2012, Dr. Baeriswyl served as a Management Consultant with the healthcare practice of the Boston Consulting Group. From 2007 to 2008, Dr. Baeriswyl managed a family-owned medical practice. Dr. Baeriswyl holds a Ph.D. from the University of Paris Descartes and a diploma from the University of Basel (M.Sc. equivalent).

CHIEF OPERATING OFFICER

CHRISTOPHE BONNY

cb

Christophe Bonny has served as our Chief Scientific Officer since 2016. Dr. Bonny has approximately 20 years’ experience in the field of molecular biology and signaling pathways and 15 years in the field of hit identification to candidate selection. Before joining us, Dr. Bonny served as the Chief Scientific Officer at Bicycle Therapeutics Limited from 2013 to 2016. From 2006 to 2012, Dr. Bonny served as the Chief Scientific Officer of Xigen SA and also served as its President from 2011 to 2012. In 2005, Dr. Bonny received the Pfizer Research Prize. Mr. Bonny holds a Ph.D. in biochemistry and molecular biology from Neuchâtel University.

CHIEF SCIENTIFIC OFFICER

MARIE-LAURE BOUTTIER

mlb

Marie-Laure Bouttier has served as our Chief Operating Officer from 2011 to 2018 and Chief Corporate Officer since 2018. Ms. Bouttier joined Fovea Pharmaceuticals SA at its inception in 2005 as a business development associate and held a position in the licensing and contractual operations through the sale to Sanofi S.A. in 2009. Ms. Bouttier then served as the Business Development & Contract Manager at Sanofi S.A. from 2009 to 2011. From 2003 to 2005, Ms. Bouttier was a business development associate at UroGene, S.A. Ms. Bouttier holds a Masters in Economics from Université Lyon 2.

CHIEF CORPORATE OFFICER

RODOLPHE CLERVAL

rc

Rodolphe Clerval has served as our Chief Business Officer since 2012. Before joining us, from 2008 to 2010,
Mr. Clerval served as the Vice President, Corporate and Business Development of TcLand Expression SA, a molecular diagnostic company. From 2004 to 2008, Mr. Clerval served as the Business Development Manager at Genzyme France. From 2001 to 2003, Mr. Clerval was an equity analyst for the brokerage firm, Natixis Bleichroeder Inc. From 1998 to 2001, Mr. Clerval served as Research Scientist at Aventis Animal Nutrition SA. Mr. Clerval holds an M.Sc. in biological engineering from Polytech Marseille and a Certified European Financial Analyst diploma from the European Federation of Financial Analysts Societies.

CHIEF BUSINESS OFFICER

CHRISTELLE DUMOUSSAUD

cd

Christelle Dumoussaud has served as our Chief Financial Officer since 2015. Ms. Dumoussaud has more than 20 years’ experience in financial departments of various industries. In 2015, Ms. Dumoussaud served as General Secretary at Laboratoire Hepatoum-Dermophil Indien and Ms. Dumoussaud served as a financial consultant at Expert & Consult in 2014. From 2012 to 2013, Ms. Dumoussaud served as Administration and Finance Manager at Almavia and from 2007 to 2012, Ms. Dumoussaud served as General Secretary at Polygon/Munters France-Belgium. Ms. Dumoussaud worked at Fournier/Solvay Pharma from 1997 to 2007, serving as the Finance Director from 2005 to 2007. Ms. Dumoussaud served as the Chief Financial Officer of Fournier Pharma Belgium from 2001 to 2004. Ms. Dumoussaud holds a Master in Business Management from the ISC Paris.

CHIEF FINANCIAL OFFICER

JAN FAGERBERG

Jan Fagerberg has served as our Chief Medical Officer since January 2019. From 2017 to December 2018,
Dr. Fagerberg served as Senior Adviser at Fagerberg Oncology SA. From 2013 to 2017, Dr. Fagerberg served as Chief Medical Officer at SOTIO a.s. From 2012 to 2013, Dr. Fagerberg served as Vice President, Global Development and Managing Director at Amgen Research GmbH. Prior to then, he served as the Senior Vice President and Chief Medical Officer at Micromet A/G from 2009 to 2012, prior to its acquisition by Amgen. Dr. Fagerberg was Medical Director at TopoTarget from 2006 to 2009. Dr. Fagerberg held various positions of increasing responsibility at Roche from 1999 to 2006 in medical and clinical operations after ten years of oncology practice and academic translational immune-oncology research at Karolinska Hospital. Dr. Fagerberg holds an M.D. and Ph.D. from the Karolinska Institute.

CHIEF MEDICAL OFFICER

CATHERINE MATHIS

Catherine has more than 25 years’ experience working in clinical research and regulatory affairs with pharma and biotech companies, especially in the areas of immunology and oncology. She developed robust expertise for developing innovative healthcare products from Phase 1 to phase 3 studies with an excellent product knowledge concerning US and EU regulations. She conducted many projects in development with interactions with the US FDA and the European health authorities (EMA and national competent authorities) including also interactions with European payers (HTA bodies). Prior to joining Enterome in March 2019, Catherine served as Chief Operating Officer at Elsalysbiotech dedicated to the development of mAbs in onco-hematology. Earlier, she took over the position of VP, regulatory affairs at TxCell in cell therapy. Prior to that, Catherine served for several years as head of regulatory affairs at Transgene developing immunotherapy products based on recombinant viruses.
She started her career at Ipsen and Sanofi Pasteur in clinical research. Catherine is Pharm D and holds a master degree in toxicology.

CHIEF DEVELOPMENT OFFICER

BOARD OF DIRECTORS

GEORGES GEMAYEL

Georges Gemayel has served as chairman of our board of directors since 2015. From June 2008 to November 2009, Dr. Gemayel served as President and Chief Executive Officer of Altus Pharmaceuticals Inc. From 2003 to 2008,
Dr. Gemayel was Executive Vice President at Genzyme Corporation where he was responsible for the company’s global therapeutics, transplant, renal and biosurgery businesses. From 1998 to 2003, Dr. Gemayel held progressively senior roles at Hoffmann La-Roche Inc. and Roche Laboratories, Inc., most recently as Vice President, National Specialty Care, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis and HIV. Dr. Gemayel currently serves on the boards of directors of U.S. publicly-traded companies, Supernus Pharmaceuticals, Inc. and Momenta Pharmaceuticals, the board of directors of Orphazyme A/S, which is publicly traded on Nasdaq Copenhagen and the boards of directors of OxThera AB and Dynacure. Dr. Gemayel received his Pharm.D. from St. Joseph University and his Ph.D. in Pharmacology from Paris-Sud University. Our board of directors believes that Dr. Gemayel’s over 25 years of experience in the biopharmaceutical industry, including management and executive positions, provides him with the qualifications and skills to serve as a director.

CHAIRMAN OF THE BOARD

PIERRE BELICHARD

pb

Pierre Belichard has served as our Chief Executive Officer since 2011 and as a member of our board of directors since 2011. Previously, Dr. Belichard served as Vice President of Mergers and Acquisitions and Business Development at Sanofi Ophthalmology from 2009 to 2011. Dr. Belichard was the Founder of Fovea Pharmaceuticals SA. and served as the Chief Operating Officer from 2005 to 2009. From 2002 to 2004, Dr. Belichard served as Vice President of Business Development at UroGene, S.A., a company acquired by Pierre Fabre in 2004. From 2000 to 2002, he served as head of European commercial operations at Ethypharm S.A. Dr. Belichard holds a Pharm.D. from Grenoble Faculty of Medicine and Pharmacy, Ph.D. from University Pierre and Marie Curie and an M.B.A. from INSEAD. Our board of directors believes that Dr. Belichard’s leadership of our company since its inception and experience with biopharmaceutical companies prior to founding our company provides him with the qualifications and skills to serve as a director.

CHIEF EXECUTIVE OFFICER

PIERRE CASSIGNEUL

Pierre Cassigneul has served as a member of our board of directors since 2013. Mr. Cassigneul has served as the President and Chief Executive Officer at NMS Labs, Inc. since 2013. Before that, from January 2013 to May 2013, Mr. Cassigneul was Chief Executive Officer at Predictive Biosciences and, from 2003 to 2012, President and Chief Executive Officer at XDX Inc. Mr. Cassigneul served as the Vice President, Diabetes Management at Becton Dickinson & Company from 2001 to 2002, Senior Vice President, Business Operations at Bayer U.S. from 1997 to 2001 and Business Unit Vice President & General Manager at Johnson & Johnson from 1991 to 2001.

Mr. Cassigneul currently serves on the board of directors of NMS Labs, Inc. Mr. Cassigneul holds an M.B.A. equivalent from Ecole Supérieure de Commerce de Reims. Our board of directors believes that Mr. Cassigneul’s experience in the pharmaceutical industry provides him with the qualifications and skills to serve as a director.

DIRECTOR / INDEPENDENT

ISABELLE DE CREMOUX

Isabelle de Cremoux has served as a member of our board of directors since 2008. From June 2017 to June 2018, Ms. de Cremoux served as representative of Seventure Partners, the legal entity that held this board seat during that period. Since 2001, Ms. de Cremoux has served as Chief Executive Officer and Managing Partner of Seventure Partners, where she established and leads the life sciences team. Previously, Ms. de Cremoux worked at Arthur Andersen LLP from 1991 to 1993. From 1998 to 2001, Ms. de Cremoux served as Deputy Director of Business Development at Laboratoire Fournier S.A.S. / Abbott Laboratories. From 1993 to 1998, Ms. de Cremoux worked at Pfizer France and Pfizer Europe, where she held various positions within management, clinical research and business development. Ms. de Cremoux holds a degree in Engineering from l’Ecole Centrale Paris. Our board of directors believes that Ms. de Cremoux’s experience in the pharmaceutical industry, including management and executive positions, provides her with the qualifications and skills to serve as a director.

DIRECTOR / SEVENTURE PARTNERS

ROGER GARCEAU

Roger Garceau has served as a member of our board of directors since 2016. Dr. Garceau is a board certified pediatrician with approximately 30 years of experience in pharmaceutical development, global regulatory and medical affairs. From 2008 to 2016, Dr. Garceau worked at NPS Pharmaceuticals. From 2002 to 2008,
Dr. Garceau worked at Aventis/Sanofi Pharmaceuticals. Dr. Garceau currently serves on the board of directors of EnteraBio Ltd. Dr. Garceau holds a B.S. from Fairfield University and an M.D. from University of Massachusetts Medical School. Our board of directors believes that Dr. Garceau’s experience in the pharmaceutical industry, as well as his medical and scientific background, provides him with the qualifications and skills to serve as a director.

DIRECTOR / INDEPENDENT

HANS-JUERGEN WOERLE

Coming soon.

DIRECTOR / NESTLÉ

JOHAN KÖRDEL

Johan Kördel has served as a member of our board of directors since 2012 and has served as representative of Lundbeckfonden Invest A/S, the legal entity that holds this board seat, since 2017. Dr. Kördel has served as the Senior Partner at Lundbeckfonden Ventures since 2010. Before joining Lundbeckfonden Ventures, Dr. Kördel worked 20 years in the pharmaceutical and biotech industry with structural biology, management of research and early development, portfolio management, business development and alliance management. From 2008 to 2010, Dr. Kördel served as Co-Founder and Chief Executive Officer of Sound Biotech ApS. From 2001 to 2006, Dr. Kördel served as Co-Founder and Senior Vice President of Research and Business Development of Biovitrum AB. From 1992 to 2000, Dr. Kördel worked at the pharmaceutical company, Pharmacia Corporation. Dr. Kördel currently serves on the board of directors of Acadia Pharma Group plc, which is publicly traded on Euronext Brussels.

Dr. Kördel trained as a physical chemist at University of Lund, Scripps Research Institute and Harvard Medical School. Since 1994, Dr. Kördel has been an associate professor of Physical Chemistry at the University of Lund. Our board of directors believes that Dr. Kördel’s experience in the pharmaceutical industry, including management and executive positions, provides him with the qualifications and skills to serve as a director.

DIRECTOR / LUNDBECKFONDEN VENTURES

ANDREA PEDERZOLLI

Andrea Pederzolli has served as a member of our board of directors since March 2018 and has served as representative of Principia SGR SpA, the legal entity that holds this board seat, since June 2018. Since 2017,
Mr. Pederzolli has been a general partner at Principia SGR, a venture capital manager in Italy. Mr. Pederzolli started his career as an electronic engineer designing satellite communication networks and later moved to the financial sector working in London at the Industrial Bank of Japan as an Associate, Structuring and Customer Risk Management from 1994 to 1996, Barclays Capital as Medium Term Notes Associate Director from 1997 to 1998, and Merrill Lynch as Vice President Corporate Risk Management from 1998 to 1999. In 2000, Mr. Pederzolli founded MangustaRisk. Mr. Pederzolli holds an M.Sc. in finance from the London Business School (UK) and an engineering degree in electronic engineering from the University of Rome (Italy). Our board of directors believes that Mr. Pederzolli’s experience in the financial sector provides him with the qualifications and skills to serve as a director.

DIRECTOR / PRINCIPIA

MARY THISTLE

Mary Thistle has served as a member of our board of directors since 2017. Since January 2018, Ms. Thistle has served as the Chief of Staff at the Bill & Melinda Gates Medical Research Institute. From 2015 to 2017, Ms. Thistle served as the Chief Operating Officer at Dimension Therapeutics, Inc. From 2009 to 2015, Ms. Thistle served in several roles at Cubist Pharmaceuticals Inc., including most recently as Senior Vice President, Corporate Development and Integration Management. Prior to this, from 1997 to 2008, Ms. Thistle held leadership positions at ViaCell, Inc. Ms. Thistle is currently a member of the board of directors for Homology Medicines, Inc. where she is the chair of the audit committee. Ms. Thistle is also on the board of directors for Coccon Biotech, Inc. Ms. Thistle began her career in finance as a certified public accountant working with both private and public companies. She received her B.A. in accounting from the University of Massachusetts. Our board of directors believes that
Ms. Thistle’s experience in finance, operations and business development, as well as her experience in the life sciences industry, provides her with the qualifications and skills to serve as a director.

DIRECTOR / INDEPENDENT

TECHNOLOGY

Two complementary metagenomic platforms for a full genomic and functional analysis of the microbiome

A QUANTITATIVE METAGENOMICS PLATFORM

based on full sequencing and mapping of total fecal bacterial gene content that allows the characterization of a personal metagenome (metagenotype®) associated with a disease phenotype. This technology enables the identification of biomarkers and of bacteria of interest associated with the development of diseases.

A FUNCTIONAL METAGENOMICS PLATFORM

based on the screening of genomic or metagenomics libraries on cell based assays and on specific pathways of interest that allows the discovery and the development of news drugs and targets.

PROGRAMS & PRODUCTS

CROHN DISEASE & IBD

EB8018

EB8018 is a first-in-class, orally administered small molecule that is specifically designed to remain gut-restricted, and has shown minimal absorption into the bloodstream. It is designed to prevent (i) FimH-expressing bacteria from adhering to the gut wall, (ii) activation of innate immune receptors, (iii) induction of gut permeability and (iv) ultimately, inhibition of the bacterial translocation through the gut wall—all shown to contribute to reducing the inflammatory cascade underlying Crohn’s disease.

MORE ABOUT EB8018

Our lead product candidate, EB8018, is a first-in-class, non-systemic, orally administered small molecule that is specifically designed to remain gut-restricted and to block bacteria expressing the bacterial virulence factor, FimH, a key inducer of the inflammatory cascade in the intestine, thereby decreasing intestinal inflammation in patients with Crohn’s disease. Crohn’s disease is an inflammatory bowel disease which causes chronic inflammation in a patient’s digestive tract, and leads to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. In studies of Crohn’s patients, we observed a common pattern of imbalance of the gut’s bacterial composition, characterized by a bloom of Enterobacteriaceae, a large family of bacteria that includes Escherichia coli, or E. coli. Utilizing our proprietary platform to analyze the relative abundance of all microbiome genes, we sequenced the bacterial genomic material that we isolated from microbiome samples of Crohn’s patients and we observed that the FimH gene, expressed by Enterobacteriaceae, was up to 160 times more abundant in patients with Crohn’s disease than in healthy volunteers. We believe EB8018 has the potential to treat patients with various subsets of inflammatory bowel disease, including Crohn’s disease, as well as in different therapeutic settings, such as patients with chronic active disease, in post-surgery or requiring a maintenance therapy to maintain remission. We have entered into a global strategic alliance with Takeda Pharmaceutical Company Limited, or Takeda, for the co-development and co-commercialization of EB8018. We expect to report preliminary data from a Phase 1b clinical trial of EB8018 for the treatment of Crohn’s disease in 2019. In collaboration with Takeda, we have designed a Phase 2a clinical trial of EB8018, and we expect to commence enrollment of this trial in 2019.

EB420

EB420 is a therapeutic program for the discovery of new drug candidates for the treatment of Inflammatory Bowel Diseases. Enterome and Takeda Pharmaceutical jointly collaborate for the development of new drug candidates for the treatment of severe GI disorders.

EB110

EB110 is a therapeutic program for the discovery of new drug candidates in Crohn’s Disease. Enterome and Johnson & Johnson jointly collaborate for the discovery of novel target and microbiome derived bioactive molecules.

IMMUNO-ONCOLOGY

EO2401

EO2401 is an innovative, off-the-shelf immunotherapy comprised of three onco-mimics, which are highly homologous to solid tumor antigens. EO2401 mimics three key tumor antigens that are highly expressed by brain tumors, including GBM, as well as other tumor types.

EO2401 aims to target the patient’s dendritic, or antigen-presenting, cells to induce efficient presentation of cancer epitopes to T cells that, in turn, leads to a sustained immune response against cancer cells expressing the same antigens at the tumor site.

MORE ABOUT EO2401

Our second product candidate, EO2401, is an innovative, off-the-shelf immunotherapy comprised of three microbiome-derived antigens, which are highly homologous to solid tumor antigens. We refer to these microbiome- derived antigens, which are bacterial short peptides that have high amino acid sequence homology with known human tumor antigens and neoantigens, as onco-mimics. EO2401 mimics three key tumor antigens that are highly expressed by brain tumors, including glioblastoma multiforme, or GBM, as well as other tumor types. Because of its bacterial origin, EO2401 elicits a significantly greater CD8+ T cell driven immune response when administered with an adjuvant than the homologous tumor antigens on their own. Furthermore, we have demonstrated that this response is synergistic when combined with checkpoint inhibitors both in vitro and in vivo. We expect to initiate a Phase 1b/2a clinical trial of EO2401 in combination with a checkpoint inhibitor for the treatment of GBM in 2019.

We are also designing a second Phase 1b/2a clinical trial of EO2401 that will aim to enroll patients for the treatment of a range of other solid tumors. Beyond EO2401, we have filed a patent application covering 580 novel onco-mimics to date, targeting 78 human tumor antigens highly expressed in 20 broad tumor types, and we plan to continue to explore other combinations of onco-mimic candidates for the treatment of various forms of cancer.

 

EO520

EO520 is a therapeutic program for the discovery of new drug candidates for the treatment of cancer. Enterome and Bristol-Myers Squibb jointly collaborate for the discovery of novel biomarkers.

bms2

EO510

EO510 is a therapeutic program for the discovery of new drug candidates for the treatment of divers types of cancer such as glioblastoma, colon, pancreatic, lung and breast. This therapeutic program enables Enterome to discover microbiome related antigen mimics (« onco-mimics ») of cancer antigens.

PIPELINE

INVESTORS

Our company has been established in 2012 and has already raised a 63.8M€ in four rounds with private equity funds (Seventure, Omnes Capital, Lundbeckfonden, Health for Life Capital, Principia SGR) and strategic investors (INRA Transfert, Shire, Nestlé, BMS).

MORE ABOUT

Being one of the leading venture capital firms in Europe, Seventure manages €500m and invests since 1997 in innovative businesses with high growth potential in IT and in Life Sciences. With preferred sectors of Biotech & Pharmaceuticals, Medtech, Industrial Biotech & Cleantech, and Lifestyle Healthcare & Nutrition. Seventure is a subsidiary of Natixis.

MORE ABOUT

Lundbeckfonden Ventures is a life science venture fund established in 2009 and wholly owned by the Lundbeck Foundation. On an annual basis, Lundbeckfonden Ventures invests up to € 50 million. Investments are made within lifescience, focusing on pharmaceuticals and biopharmaceuticals, medtech, diagnostics and healthcare service companies.

MORE ABOUT

Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €2.1 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, formerly Crédit Agricole Private Equity, was a subsidiary of Crédit Agricole until March 2012 when the company was acquired by Coller Capital.

MORE ABOUT

Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and its partners in healthcare. Nestlé Health Science’s portfolio of nutrition solutions, diagnostics, devices and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide. For more information, please visit: www.nestlehealthscience.com.

MORE ABOUT

Health for Life Capital supports innovative high-growth entrepreneurial ventures. Geographically, its focus is primarily in Europe, but also extends to North America and Asia. Investments will be made in the areas of healthcare, life sciences, biotechnology, medical technologies, pharmaceuticals, nutrition and in the emerging fields of microbiome and connected health.

MORE ABOUT

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

MORE ABOUT

Principia SGR, founded in 2002, is one of the leading Italian venture capital operators. The SGR currently manages 4 investment fund: Principia II, Principia III – Health, Principia IV – Alis and Principia V Utopia. The fund Principia III – Health, dedicated to Venture and Growth capital investments in the Healthcare sector, raised 206 million euros, and made 9 investments as of today deploying 80 million euros. Principia IV – Alis is the fourth Fund of the SGR dedicated to the development of the excellence of Made in Italy, focused on fashion and design. The fund it is currently in fund raising. Principia Utopia is the most recent Fund launched by Principia with a target size of €70 million. The Fund has a very well-defined strategy: funding and supporting Life-Tech start ups for patents development in the first and second stage with management of the intellectual property. The focus will be on projects that develop molecules, curative devices and advanced diagnostics for prevention.

PRESS, NEWS & EVENTS
NEWS & EVENTS
19Oct

UEGW

October 19-23 - Barcelona (Spain) Read More →
05Nov

CPhI Worldwide

November 5-7 - Frankfurt (GER) Read More →
06Nov

SITC

November 6-10 - Washington (US) Read More →
08Nov

AASLD

November 8-12 - Boston (US) Read More →
04Dec

BioData World

December 4-5 - Basel (Switzerland) Read More →
07Dec

ASH (American Society of Hematology)

December 7-10 - Barcelona (Spain) Read More →
MORE NEWS & EVENTS

ENTEROME  IS GROWING, APPLY TODAY AND BECOME A PART OF OUR SUCCESS!

We are an innovation-driven company with a strong team spirit as well as a great place to work where you can get things to move.

Working in lean teams for a human-size company, you will get a real mission with objectives to fulfil : flexibility and scope of action is wide, and learning becomes a daily routine.

Also, you will get a chance to quickly take ownership and increase your responsibilities.

The solutions we deliver are the sum of our collective talents, and we believe the best results arise from integrating a mix of perspectives and experiences.

Furthermore, as you get involved and enjoy what you do, we make sure you get recognition for your achievements.

We need enthusiastic and passionate new hires to take on challenges and develop our business.

If you wish to acquire key competencies and to develop them, Enterome is the place to be.

If you have a positive, proactive, startup mentality, and are interested in joining a highly disruptive life science business on the forefront of the burgeoning microbiome industry:

ENTEROME  WANTS YOU!

JOB OFFERS
30Jul

QA/QC Manager

In the context of the set-up of a new software application for the management of the company Quality System, we are seeking a quality assurance/control Read More →
29Jul

Medical Writer

This new team member is capable of the creation and amending, any type of clinical regulatory document according to company guidelines and international governmental regulations Read More →

We are currently expanding our Immuno-Oncology department and are looking for new talented people to join our team from leadership positions to research and development functions.

Apply now and become part of an amazing adventure in Life Sciences at Enterome.

APPLY NOW
ENTEROME FRANCE

Headquarters

94/96 avenue Ledru-Rollin 75011 Paris – France Tel : +33 (0)1 75 77 27 85

Lab facilities

Biocluster Genopole – 5 rue Henri Desbruères – 91030 Evry Cedex

ENTEROME USA

Subsidiary

One Broadway, 14th Floor, Cambridge MA 02142, USA

CONTACT US

Your Name (required)

Your Email (required)

Category

Subject

Your Message

Attached file #1 (5Mo - pdf, doc, docx, rtf)

Attached file #2 (5Mo - pdf, doc, docx, rtf)

By submitting your information in this e-mail message, you agree that such information will be governed by our Privacy Policy related to personal datas.